ARGX
argenx SEANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Successful clinical readouts, expanding reimbursement and efficient commercial scale for efgartigimod drive >50% revenue growth and multiple expansion; pipeline assets add further upside.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +4.6.
What can break
Commercial execution shortfalls post-launch
Momentum
70
Value
54
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-10 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $1,029.81
Why
Momentum70 · Δ7d +4.6
Value54 · Δ7d +0.2
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
70
52% active weight
Current posture
7d trendImproving
Δ7d
+4.6
Δ21d
+22.6
Value
54
48% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
+0.3
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 69.9 / Value 54.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$51.68B
Beta
0.72
Shares Out
61.57M
P/E (TTM)
34.6
P/S (TTM)
13.68
P/FCF (TTM) · Derived
-342.23
Rev YoY
+96.6%
EPS YoY
+272.7%
Gross Margin
+89.6%
Op Margin
+21.9%
Net Debt
-$3.34B
Current Ratio
5.60
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology